Maxim starts Ceplene Phase III

Maxim (MAXM; SSE:MAXM) started in the U.S., EU and Canada a 224-patient Phase III trial of its Ceplene (formerly Maxamine) histamine dihydrochloride and IL-2 or IL-2 alone to treat metastatic melanoma...